Plüss H J, Hitzig W H
Schweiz Med Wochenschr. 1980 Oct 4;110(40):1459-62.
From 1964 to 1979, 57 children with acute myelocytic leukemia have been treated at the University Children's Hospital, Zürich. The overall remission rate was 0.60, with a median remission duration of 2 months and survival of 6.4 months. Patients with FAB type M 1 responded best, but longtime survivors were observed from all FAB types. Whereas in the 1960s only 4/19 achieved (short) remission, now, since the introduction of cytosine arabinoside, remissions are observed on 79% but median survival (10 months) is still short compared with acute lymphocytic leukemia. However, 11/38 children treated since 1971 survived for more than 2 years. Four of these relapsed (after less than 23 months of complete remission), while of the remaining seven, 5 have been off treatment for 5 to 77 months. This group includes children of both sexes, all ages, low and high WBS's, with organ infiltrates (excluding CNS and skin), and in whom the time taken to achieve M 1 marrow played no role. These results show that, with combination chemotherapy including cytosin arabinoside, remission can almost always be attained, but prolonged remission can be maintained only in about 1/5 of these children. The problems of maintenance treatment and CNS-prophylaxis need more attention in the future.
1964年至1979年期间，苏黎世大学儿童医院共治疗了57例急性髓细胞白血病患儿。总体缓解率为0.60，缓解期中位数为2个月，生存期为6.4个月。FAB分型为M1型的患者反应最佳，但所有FAB分型均有长期存活者。20世纪60年代只有4/19的患者获得（短期）缓解，而现在，自从引入阿糖胞苷以来，缓解率达到79%，但与急性淋巴细胞白血病相比，中位生存期（10个月）仍然较短。然而，自1971年以来接受治疗的38例患儿中有11例存活超过2年。其中4例复发（完全缓解不到23个月后），其余7例中，5例已停止治疗5至77个月。这组患儿包括不同性别、各年龄段、白细胞计数高低不同、有器官浸润（不包括中枢神经系统和皮肤）的患儿，且达到M1骨髓状态所需时间对此并无影响。这些结果表明，采用包括阿糖胞苷在内的联合化疗，几乎总能实现缓解，但只有约1/5的患儿能够维持长期缓解。维持治疗和中枢神经系统预防问题在未来需要更多关注。
